Priyanka Chigurupati, who oversees Granules India Ltd's crucial US operations, is leading a strategic shift from the company's traditional role as a high-volume Active Pharmaceutical Ingredient (API) supplier towards one focused on complex formulations and geographic diversification. According to reports from Moneycontrol, Chigurupati stated that the company would be looking at M&A to achieve its objectives, noting they are "very, very open to looking at M&A" while scouting for front-end assets in Europe and specialized manufacturing capabilities that fit their complex generic roadmap. This strategic approach aligns with broader industry trends, as the global solids feeder market is experiencing significant growth driven by automation and Industry 4.0 integration, with investments in industrial automation projected to grow at a compound annual growth rate of over 8%.
The US market currently accounts for approximately 77 percent of Granules India's ₹3,453 crore revenue, leaving the firm exposed to regional pricing pressures and regulatory uncertainties. As reported by Moneycontrol, the company has established a German entity for European expansion and a new Canadian subsidiary, while also looking at Latin America, with Brazil as one of its focused markets. The company aims to launch products in higher-margin complex generics categories including oncology and peptides by fiscal 2028. This diversification strategy mirrors broader pharmaceutical industry trends, where the global pharmaceutical sector surpassed $1.4 trillion in revenue, with regulatory mandates like Good Manufacturing Practices (GMP) necessitating high-precision feeding systems for active pharmaceutical ingredients (APIs) and excipients.
To fund this transition and strengthen the balance sheet, Granules India completed a ₹1,762.50 crore capital-raise in February 2026. According to Moneycontrol, these funds are earmarked for scaling operations, settling vendor payments, and expanding capacity—specifically tripling certain formulation outputs. The company's strategy of strengthening vertical integration has sharply increased the share of high-margin finished dosages, which accounted for more than three-fourths of revenue in FY25, from less than 50 percent before FY23. This investment approach reflects the pharmaceutical industry's focus on advanced manufacturing capabilities, with regulatory mandates like GMP driving demand for precise feeding systems that ensure product consistency and quality.
Progress in the US pipeline is tied to resolving regulatory issues at the Gagillapur facility in Telangana, which received a USFDA warning letter in 2025. As reported by Moneycontrol, Chigurupati stated the company is ready for USFDA re-inspection and aims for quick resolution, as clearing the facility is essential for the broader launch of new products, including the future oncology pipeline. The company remains one of the world's largest suppliers of paracetamol, holding 20 percent global share and second-largest in regulated markets. This market position is supported by the global chemical industry's robust growth, particularly in the Asia-Pacific region, with an estimated market value exceeding $5 trillion and driving demand for precise material handling equipment.
The company continues to face logistics challenges due to unrest in West Asia, with shipping lines taking longer routes increasing both lead times and freight costs. According to Moneycontrol, Chigurupati noted that while "logistics are definitely getting more expensive," the company is leveraging its multi-site manufacturing and strategic inventory positioning to manage these disruptions. She emphasized that "the next three years are about building the foundation for the next decade" as the company navigates both geopolitical headwinds and a transition toward complex medicine. The company's strategic focus on complex generics and geographic diversification positions it well for the future, as the global solids feeder market is experiencing significant growth driven by automation trends and Industry 4.0 integration across various sectors.
